Factsheet and Information Brochure
Factsheet
Target Market
Costs and charges
Fund rules (190 kB)
Prospectus (1369 kB)
Periodic reports
Sustainability SFDR (995 kB)
Annual review (PF) (3106 kB)
Semi-annual report (PF) (200 kB)
Marketing material
Sustainability profile
Brief fund information
Summary SFDR (171 kB)
Handelsbanken Hälsovård Tema (A1 NOK)
Legal name: Handelsbanken Hälsovård Tema (A1 NOK)
Equity Fund Registered in Sweden (UCITS)
Bid
About risk
Historical yields are not a guarantee of future returns. A fund can both increase and decrease in value and it is not guaranteed that you will recover the entire invested amount. Note that a fund with risk level 5-7, as stated in the fund's fact sheet (KID), can vary greatly in value due to the fund's composition and management methodology. The prospectus, fund rules and KID are available under each fund. Summary of investors' rights.
The fund is actively managed and invests globally in equities issued by companies within the healthcare sector. As a result, the fund has a currency exposure to these markets. The healthcare sector refers to the pharmaceutical, medical technology, biotech, service and other healthcare-related branches.
The thematic investment strategy provides for investments that occur in a limited area in which development is deemed to result in a structural change to the economy and society. This change provides favorable conditions for companies active within the area to create profitable growth over time.
For this fund, the fund company's Enhanced exclusion level applies. For information about sectors that the fund excludes, see the Detailed information tab.
The fund is reported as an Article 9 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).
The thematic investment strategy provides for investments that occur in a limited area in which development is deemed to result in a structural change to the economy and society. This change provides favorable conditions for companies active within the area to create profitable growth over time.
For this fund, the fund company's Enhanced exclusion level applies. For information about sectors that the fund excludes, see the Detailed information tab.
The fund is reported as an Article 9 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).
Fund Spotlight
The fund rules will be changed on 10 October 2025.Read more
Fund manager
Christopher Sundman Experience in the fund industry 1987. Portfolio Manager since 1 August 2022.
Fund manager
Caroline Banér Experience in the fund industry 2009. Portfolio Manager since 1 October 2024.
|
|
||
|---|---|---|---|
|
The risk indicator provides guidance on the risk level for this product relative to other financial products. It shows the likelihood that the product will decrease in value due to market performance. Risk level 1 represents a low risk and risk level 7 is a high risk.
|
|
30.06.2025
|
||
|---|---|---|---|
|
The rating shows which funds have historically posted the strongest performance in relation to risk. Ratings are denoted by a scale of one to five stars, with five as the highest rating. A fund must have a performance history of at least three years to receive a rating.
Read more about the fund's rating |
|
|
||
|---|---|---|---|
|
The fund has sustainable investments as its objective. Accordingly, the fund invests in companies with products and services that are considered as contributing positively to the direct fulfillment of one or several of the targets in Agenda 2030. Refer to the fund's prospectus for additional information. The fund is reported as an Article 9 fund pursuant to EU regulation on sustainability-related disclosures in the financial services sector (SFDR). Read more |
|
30.04.2025
|
|||
|---|---|---|---|
|
The sustainability rating is developed by the fund information company Morningstar. The rating measures how well the fund's investee companies manage sustainability risks relative to other funds within the same global Morningstar category. If the fund has invested in government bonds issued by sovereign states, the respective country's sustainability risk is included in the calculation. The analyzed funds can receive a sustainability rating between 1 and 5 globes, with 5 as the highest rating. The fund complies with the UN Principles for Responsible Investments. |
Graph
Performance
| Rate 10.07.2025 | 1 week | 1 month | 3 months | 2025 | 1 year | 5 years | 10 years |
|---|---|---|---|---|---|---|---|
| 410.52 NOK | 1.25% | 0.37% | -4.16% | -12.05% | -15.75% | 38.83% | 153.39% |
Portfolio 09.07.2025
Portfolio manager comments — Q2 2025
Fund performance was weak during the second quarter and declined by 10% in SEK.
The main reason was continued uncertainty related to the Trump administration’s trade policy, particularly regarding tariffs and proposals to align US drug prices with international levels.
The largest negative contributor was UnitedHealth, which continues to face profitability pressure and risks related to potential changes in the US healthcare system that could negatively impact its business model. The company has long been one of the fund’s largest holdings and a significant positive contributor, but now we have substantially reduced the position.
On the positive side was the Belgian pharmaceutical company UCB, which continues to gain market share with its psoriasis drug Bimzelx. The company also has regulatory applications under review for additional dermatological indications.
The fund also benefited from holdings in diagnostics companies Natera (US) and Devyser (Sweden), both of which contributed positively during the period.
On the negative side was Japan’s Daiichi Sankyo, which declined after clinical trial results failed to meet market expectations. However, we believe the company’s research pipeline still has the potential to deliver positive surprises.
In the obesity segment, Zealand Pharma continued to underperform, which may seem contradictory given its recently announced partnership with Roche—a collaboration that could generate significant revenue in the coming years.
Argenx also contributed negatively after some patients failed to respond as expected in CIDP treatment studies.
New holdings include Nurix Therapeutics, a biotech company focused on degrader technology, and China’s CSPC Pharma, which collaborates with companies including AstraZeneca in AI and drug development.
Valuations in the healthcare sector have come down significantly this year, making the area more attractive. However, greater clarity is needed regarding tariffs and the Trump administration’s MFN proposal before the market can fully price in the underlying demand.
Portfolio distribution 30.06.2025
Geographic breakdown 30.06.2025
